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- Squamous cell carcinoma (80%) 
- Adenocarcinoma (10%)  
- Adenoacanthoma (10%) 
Clinics and pathology 
Disease 
Carcinoma of the cervix uteri; usually arises in the 
transitional zone between squamous and columnar cell 
epithelium. 
Etiology 
Infection with high-risk forms of the human 
papillomavirus (HPV) is established as the major 
factor: a secondary factor is cigarette smoking; recent 
evidence suggests that a polymorphic variant of the 
tumour suppressor P53 (p53Arg) may represent a risk 
factor for cervical carcinogenesis. 
Epidemiology 





Cervical smears confirm the diagnosis of carcinoma or 
may reveal the presence of the disease in its 
preinvasive (preclinical) stage. 
Pathology 
Three grades of preinvasive carcinoma-in-situ (CIN) 
are recognised: I (which usually undergoes spontaneous 
resolution), II and III; 
Carcinomas are staged as follows:  
 
- IA: early invasive, not grossly visible;  
- IB: usually grossly visible, but confined to the cervix;  
- IIA: spread to the upper two thirds of the vagina only; 
- IIB: lateral extension into the parametrium;  
- IIIA: involvement of the lowest third of the vagina;  
- IIIB: involvement of the pelvic side wall or 
hydronephrosis;  
- IVA: bladder or rectal involvement; 
- IVB: distant metastasis. 
Treatment 
Radiotherapy and/or surgery; late stages: radiotherapy 
supplemented by chemotherapy (e.g. cisplatin). 
Evolution 
Preinvasive stage, detectable by cervical cytology, 
shows a peak incidence between 25 and 40 years; that 
of invasive cancer is 40-50 years, thus indicating that 
the preinvasive usually progresses to the invasive stage 
over a very prolonged period. 
Prognosis 
Preinvasive lesions are curable by local removal; stage 
I and early IIA cases may expect 80-90% five year 




Polyploidisation, with modes in the triploid region or 
above, is common, particularly in the preinvasive phase 
where it may be linked to the frequent spindle 
anomalies that result, for instance, in the "three group" 
metaphases seen in histological sections and 
chromosome preparations; structural changes are 
commonest in chromosomes 1, 3, 5, 11 and 17 where, 
except in chromosome 5, they most often result in 
short-arm deletions. 
Cytogenetics Morphological 
Chromosome 1: changes may also result in the 
acquisition of additional long-arm material (as is 
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common in other types of carcinoma), e.g. in the form 
of a 1q isochromosome. 
Chromosome 3: additional material on 3q has been 
shown by comparative genomic hybridization (CGH) in 
90% of carcinomas and this gain may occur at the point 
of transition from severe dysplasia to invasive 
carcinoma; loss of heterozygosity (LOH) studies 
indicate that there are two regions on 3p where tumour 
suppressor genes may be situated: at 3p14.2 (FHIT 
gene) and at 3q21, gene not yet identified. 
Chromosome 4: LOH studies suggest that at least two 
genes are important, at 4p16 and 4q21-35. 
Chromosome 5: an i(5p), often in two or more copies, 
is a frequent finding in cervical carcinomas, and this is 
consistent with CGH studies which show amplification 
of 5p, particularly in advanced stages. 
Chromosome 6: LOH studies show a high frequency of 
loss in the region 6p21.3-p25. 
Chromosome 11: possible gene loss on both 
chromosome arms are suggested by LOH studies, at 
11p15 and 11q23; identities of the genes have yet to be 
determined. 
Chromosome 17: G-banding and LOH studies have 
shown the nonrandom loss of 17q, where the P53 gene 
is situated (at 17p13.3); mutations or loss of this gene 
are, however, relatively infrequent compared with other 
types of tumour, perhaps because there is instead 
interaction between p53 protein and the HPV E6 viral 
gene in most carcinomas of the cervix; indeed, p53 
appears to be more frequently mutated in HPV-
negative tumours. 
Role of HPV; types 16 and 18 are associated with about 
70% of cervical carcinomas (other high-risk types 
include 31, 33, 35, 39, 51, 52, and 56); these high-risk 
types are often demonstrable in the moderate and 
severe stages of preinvasive malignancy (CIN II and 
III); in these lesions they are commonly situated 
extrachromosomally while in carcinomas they are 
integrated into chromosomes at random locations, 
where they undergo disruption of the HPV E2 viral  
transcriptional regulatory protein; integration may 
thereby provide a selective advantage resulting in 
uncontrolled cellular proliferation leading to 
aneuploidy. 
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